Paul Hunter Tribute – Snooker champion and Neuroendocrine Cancer patient

Translate

Paul Hunter, three-time Masters snooker champion was just 27 when he fell victim to Neuroendocrine Cancer at the peak of his powers and popularity. At just 25, he’d won the third Masters title, a feat which, at the time, had been achieved by only two other players in the world. He was dubbed the “Beckham of the Baize” because of his chiselled good looks and long, blond hair (a reference to famous footballer David Beckham).

The Masters Trophy is one of the prestigious titles in the international snooker world and it was a belated honour that the trophy was renamed “The Paul Hunter Trophy” in 2016 at the 10th anniversary of his death from Neuroendocrine Cancer. 

This young age is unlike the majority of Neuroendocrine Cancer patients who are diagnosed in their later years. I took to the internet to find out more. Although there are many sites and articles confirming the link to “Neuroendocrine Tumours” in the annals of the internet, many sites state “stomach cancer” (some as late as 2017) but it’s a clue to the location of this cancer. However, I found via a snooker source (Ronnie O’Sullivan), a detailed story from his wife Lindsay providing information about this diagnosis and treatment – you can read this here but I’ll summarise the top-level chronology below:

2004 – Towards the end of the year, Paul started to suffer from intermittent pains in his side.

2005 – At the beginning of that year, the pain was constant, so he went to see his GP, who referred him to a consultant fearing appendicitis. An abdominal scan revealed that Paul’s appendix was fine, but there were six cysts in his abdomen. The consultant performed a laparoscopy, an outpatient procedure where the abdomen is pumped with gas and a biopsy taken. It showed that the cysts were, in fact, tumours – and they were malignant. The treatment was to be chemotherapy: ongoing cycles of three sessions of three days each.

(2 days after this diagnosis, Paul left for the China Open. It had been arranged months in advance and as he would be away just over a week he wanted to carry on as normal. Despite the diagnosis, me managed to reach the last 8).

April 2005. Paul has his first appointment with a cancer specialist. He wasn’t sure what type of cancer Paul had. He suspected either a type of germ cell tumour – the kind which occur in testicular cancer, and which are relatively easy to treat with a success rate of over 90 per cent – or neuroendocrine tumours, a type of cancer with a much poorer survival prognosis of about one in three. Author’s note: Remembering this is a statement from 2005, this would indicate to me, a poorly differentiated type. A subsequent scan ruled out a germ cell cancer, and the consultant broke the bad news that neuroendocrine tumours were the most probable diagnosis. Paul and his wife were shown the output of the laparoscopy and “It looked like there were 200 tumours, not six. They looked like Maltesers when they melt and stick together – huge masses of disgusting lumps inside the abdominal cavity“. It was agreed that Paul would start his first course of chemotherapy after the 2005 World Snooker Championships, which began in Sheffield two weeks later.

(“….this time, he did not fare as well as he did in the China open and was knocked out in the first round. Everyone knew about the cancer and it was very emotional for Paul, leaving the hall to a standing ovation, wondering when he would be back”.

(“…..By a strange twist of fate, after trying for seven months, I found out I was pregnant two days before the start of Paul’s chemotherapy”).

27th April 2005. Paul began his first course of chemo. He was to be treated with the drug combination BEP, Bleomycin/Etoposide/Cisplatin. Author’s note: To me this is another indication of a poorly differentiated tumour but I also note it was 2005 without many guidelines for therapy. Cisplatin and Etoposide are commonly used in Neuroendocrine Carcinomas. Paul was also tested for Alpha Feta Protein (AFP) which is a blood tests used to detect certain cancers. The higher the score, the bigger the tumour and this was highly elevated. Author’s note: Most medical sites state that high levels of AFP can be a sign of liver cancer or cancer of the ovaries or testicles, as well as noncancerous liver diseases such as cirrhosis and hepatitis. However, I found some case studies linked to Neuroendocrine Carcinomas.
September 2005. More chemo after a tumour marker increase. Drugs were to be administered every three weeks right through to January 2006.

April 2006. Chemotherapy changed to oxaliplatin and capecitabine.

July 2006. Markers increased; scans showed growth.

September 2006. Paul is admitted to hospice.

9th October 2006. Paul died at five to eight on the evening of October 9, five days before his 28th birthday, surrounded by his family.

What I also found out was that Neuroendocrine Cancer UK (previously NET Patient Foundation) which at that time called “Living with Carcinoid”, started a website thanks to a generous donation from Paul Hunter. In the UK, we should all remember Paul and his wife Lindsay for this donation because this embryonic organisation is now one of the most innovative and quality Neuroendocrine Cancer organisations in the world.

Rest in Peace Paul Hunter. The death of the popular Yorkshireman brought immense sadness to the snooker world and to British sport.

Disclaimer

I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me. 

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.   

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Thanks for reading.

Ronny

Personal Facebook. Like this page please.
Blog Facebook. Like this page please.
Awareness Facebook Like this page please.

Sign up for my newsletters – Click Here

Disclaimer

My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient

 
 
 
Facebook
Twitter
Pinterest
WhatsApp
Email

Who needs a gallbladder anyway?

We can survive without a gallbladder, but clearly it is a useful, functioning organ, and we are better off to keep it if we can.

Read More »

Neuroendocrine Cancer Clinical Trial – Lutetium-177Lu (Satoreotide)

What is Satoreotide? It’s an agonist treatment. i.e. a ‘next generation’ radiologand for Peptide receptor radionuclide therapy (PRRT) or more specifically the radiopharmaceutical that binds

Read More »

A review of September 2023 on RonnyAllan.NET – Living with Neuroendocrine Cancer

On my website RonnyAllan.NET, September was an interesting month because I had pushed out some blogs before I went on a planned overseas holiday from

Read More »

Never mind the Bollocks – here’s the cancer

I don’t tend to share some very personal stuff, but this is on the boundary of that rule and there are some important messages to

Read More »

First and only FDA-cleared, fully automated chromogranin A assay

There has been controversy about the utility of Chromogranin A for many years now.  Specialists have been critical about its use but to be fair

Read More »

Neuroendocrine Cancer: Question, Clarify, Confirm

One of the many observations I make in my private Neuroendocrine Cancer Facebook group is the misunderstandings caused by the use of non-standard terminology combined

Read More »

Clinical Trial – Lutathera NETTER-2 Important Update

UPDATE – Sep 25th, 2023 – Novartis radioligand therapy Lutathera® demonstrated statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors

Read More »
Lanreotide: Ipsen injection devices vs generic injection devices

Lanreotide: Ipsen injection devices vs generic injection devices

Whenever I get a chance to talk to a pharma involved in somatostatin analogue injection devices, I tell them one very important thing …… “To

Read More »

Cancer doesn’t take holidays (but I do)

Glen Etive Scotland in 2018 After diagnosis in July 2010, with the exception of a planned holiday to Turkey prior to my ‘big surgery’, holidays

Read More »

5 thoughts on “Paul Hunter Tribute – Snooker champion and Neuroendocrine Cancer patient

I love comments - feel free!

%d bloggers like this:
Verified by MonsterInsights